Cara Therapeutics, Inc.
0HTC.L
London Stock Exchange15.99
USD
-0.79
- -
Cara Therapeutics, Inc.
0HTC.L
(London Stock Exchange)
Recent
price
15.99
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Cara Therapeutics, Inc. operates as a biopharmaceutical company focused on developing and commercializing novel chemical entities that selectively target kappa opioid receptors to treat chronic pruritus and pain. Its core products include KORSUVA (difelikefalin) injection, indicated for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The company is also advancing oral formulations of difelikefalin, currently in late-stage clinical trials for conditions such as notalgia paresthetica and chronic pruritus related to atopic dermatitis, non-dialysis-dependent chronic kidney disease, and chronic liver disease. Cara's pipeline emphasizes treatments that provide relief by targeting peripheral nervous system receptors while minimizing central nervous system side effects. The company operates primarily in the United States but has licensing agreements for development, manufacturing, and commercialization with partners in Japan, South Korea, and Europe, including Maruishi Pharmaceutical Co., Ltd, Chong Kun Dang Pharmaceutical, and Vifor Fresenius Medical Care Renal Pharma Ltd. Founded in 2006, Cara Therapeutics is headquartered in Stamford, Connecticut. Recent major corporate developments include a strategic merger with Tvardi Therapeutics completed in April 2025, whereby Tvardi became a wholly owned subsidiary of Cara, resulting in significant leadership changes and expansion of the combined company's pipeline to include fibrotic disease programs based on Tvardi's therapeutic platform. The merger was accompanied by a 1-for-3 reverse stock split effective April 15, 2025. This merger and related equity incentive plans aim to strengthen Cara’s position amid ongoing revenue challenges and to support its strategic shift toward broader indications. The company continues to advance key clinical programs including the KOURAGE 1 study focusing on oral difelikefalin for notalgia paresthetica, with results anticipated by mid-2025. Cara Therapeutics is classified within the biotechnology and pharmaceutical industry segments, serving patient populations suffering from chronic pruritus and other debilitating conditions requiring novel opioid receptor-targeted therapies. The company has developed collaborative and licensing partnerships to extend its geographic reach particularly in Asia and Europe. Overall, Cara Therapeutics specializes in next-generation kappa opioid receptor agonists, with a mature commercial product and several late-stage clinical assets, complemented by recent corporate restructuring and merger activities to broaden its therapeutic scope and pipeline capabilities.